|
Robert C. Shepard M.D. F.A.C.P. has been Callisto's Chief Medical Officer since August 2006. Prior to Callisto Dr. Shepard was Senior Director and Head of US Oncology at i3 Research and has served as a Medical Director of Clinical Research and Development in oncology at AstraZeneca and as Medical Officer at the oncology branch of CBER at the FDA. His previous experience includes 15 years in clinical research at Harvard Tufts Johns Hopkins and the University of Virginia where he was Principle Investigator for 29 oncology clinical trials and the PI for ECOG.
Dr. Shepard will have primary responsibility for Callisto's clinical activities. Callisto currently has two drugs Atiprimod and L-Annamycin in clinical development and presently has three Phase I/IIa clinical trials under way in multiple myeloma acute lymphocytic leukemia and advanced cancer patients. The Company recently announced its intention to initiate a Phase II clinical trial of Atiprimod in advanced carcinoid patients. | 